Kidney re-transplantation in the ipsilateral iliac fossa: a surgeon's perspective on perioperative outcome

Abstract

Background Compared to primary transplantation, ipsilateral renal re-transplantation is associated with an increased risk of surgical complications and inferior graft outcomes. This study investigates whether an ipsilateral re-transplantation approach per se is an independent risk factor for surgical complications and early graft loss. Methods In this retrospective, single-centre analysis, surgical complications and early graft outcomes of ipsilateral kidney re-transplantations from January 2007 to December 2017 were compared with primary transplantations and contralateral re-transplantations. Univariate and multivariate binary logistic regression analyses were performed to identify risk factors for surgical complications requiring surgical revision and graft loss within the first year after transplantation. Results Of the 1.489 kidney transplantations, 51 were ipsilateral, 159 were contralateral re-transplantations, and 1.279 were primary transplantations. Baseline characteristics did not differ between the ipsilateral and contralateral re-transplant recipients except for current and highest PRA levels. Major complications requiring surgical revision were significantly more frequent in ipsilateral re-transplantations (P = 0.010) than in primary transplantations but did not differ between ipsilateral and contralateral re-transplantations (P = 0.217). Graft loss within the first year after transplant was 15.7% in the ipsilateral versus 8.8% in the contralateral re-transplant group (P = 0.163) versus 6.4% in the primary transplantation group (P = 0.009). In a multivariate regression model, ipsilateral re-transplantation was not identified as an independent risk factor for complications requiring surgical revision or first-year graft loss. Conclusions Ipsilateral renal re-transplantation is no risk factor for inferior outcomes. Graft implantation into a pre-transplanted iliac fossa is a feasible and valid therapeutic option.